2018
Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma
Kaplan DE, Mehta R, D’Addeo K, Valderrama A, Taddei TH. Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma. Medicine 2018, 97: e9757. PMID: 29369224, PMCID: PMC5794408, DOI: 10.1097/md.0000000000009757.Peer-Reviewed Original ResearchConceptsAdvanced hepatocellular carcinomaHepatocellular carcinomaOverall survivalBarcelona Clinic Liver Cancer (BCLC) systemManagement of HCCVeterans Health Administration hospitalsRetrospective cohort studyFirst-line therapySimilar survival outcomesChild-TurcottePugh scoreComorbidity indexChart abstractionCohort studySurvival benefitSystemic therapyBCLC stagePrimary outcomePrescriber typeSurvival outcomesAdministration HospitalMultivariable modelProvider specialtyCancer stagingHCC diagnosis
2013
A Multidisciplinary Approach
Taddei TH. A Multidisciplinary Approach. Journal Of Clinical Gastroenterology 2013, 47: s27-s29. PMID: 23632364, DOI: 10.1097/mcg.0b013e31829331de.Commentaries, Editorials and LettersConceptsHepatocellular carcinomaPatient selectionLiver cancerManagement of HCCBurden of tumorSolid organ tumorsProper patient selectionContinuum of careEvidence-based guidancePalliative therapySystemic therapyAppropriate therapyLiver diseaseLiver functionCancer deathOrgan tumorsClinical trialsTumor boardPotential therapyNew therapiesBetter outcomesMultidisciplinary teamPatientsTherapyMultidisciplinary conference